September 11, 2017 / 5:16 AM / 15 days ago

BRIEF-SelectMDx outperforms PCA3 stratifying men for mpMRI

Sept 11 (Reuters) - MDXHEALTH SA:

* REG-SELECTMDX OUTPERFORMS PCA3 STRATIFYING MEN FOR MPMRI

* SELECTMDX FOR PROSTATE CANCER, A NON-INVASIVE LIQUID BIOPSY TEST, CORRELATES WITH MULTIPARAMETRIC MRI (MPMRI) AND OUTPERFORMS PCA3 TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below